TEL AVIV, Israel, April 27, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a Key Opinion Leader breakfast on Wednesday, May 4, 2016 from 8 am-9:30 am Eastern Time in New York City.
Timothy Cloughesy, MD, as well as VBL Therapeutics' CEO Dror Harats, MD will discuss Advances in Glioblastoma Treatment.
Dr. Cloughesy’s research has focused on clinical trials in brain cancer using targeted molecular therapies with novel clinical trial design and biomarkers in brain cancer. He provided principal leadership for the approval of bevacizumab (Avastin®) for recurrent glioblastoma, which was the first drug approved in this disease setting in over 30 years. He is recognized as a world expert in brain cancer research and has led several first-in–human studies to treat glioblastoma. He has developed a brain cancer bioinformatics database that combines clinical outcomes, imaging, and molecular analysis to enhance translational research and has the goal of using biomarkers to provide individualized care for brain cancer patients. He has authored or co-authored over 270 peer-reviewed articles on brain cancer.
Dr. Cloughesy is a Professor of Neurology at the David Geffen School of Medicine at UCLA. He is currently the director of the Neuro-Oncology Program at UCLA and the Director of the Henry Singleton Brain Cancer Research Program. He is also a member of the Brain Research Institute and Jonsson Comprehensive Cancer Center at UCLA. He received M.D. degree in 1987 at Tulane University. He completed his Neurology Residency at University of California, Los Angeles and fellowships in Clinical Neurophysiology (UCLA 1991-1992) and Neuro-Oncology (Memorial Sloan Kettering Cancer Center 1992). Dr. Cloughesy is board certified in Neurology and Clinical Neurophysiology.
The event is intended for institutional investors and sell-side analysts only. If you would like to attend in person, please contact Mac MacDonald at 212-915-2567 or via e-mail at email@example.com to reserve a place.
A live webcast of the event (with slides) will be available at http://lifesci.rampard.com/20160504/reg.jsp. This webcast will also be available in the investors section of the Company’s website at http://ir.vblrx.com/.
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company's lead oncology product candidate, VB-111, is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. VB-111 is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >170 cancer patients and we have observed its efficacy signals in an ”all comers“ Phase 1 trial as well as in three tumor-specific Phase 2 studies. The mechanism of VB-111 combines blockade of tumor vasculature with an anti-tumor immune response. This mechanism retains activity regardless of baseline tumor mutations or the identity of the pro-angiogenic factors secreted by the tumor. VB-111 is currently being studied in a Phase 3 pivotal trial for Recurrent Glioblastoma (rGBM). The trial is being conducted under an FDA Special Protocol Assessment (SPA), and VB-111 has obtained fast track and Orphan designations.
Avastin® is a registered trade name of Genentech Inc.
INVESTOR CONTACT: Michael Rice LifeSci Advisors, LLC (646) 597-6979
Source: VBL Therapeutics